The fanconi anemia pathway limits human papillomavirus replication

Journal of Virology

Volumn 86, Issue 15, 2012, Pages 8131-8138

  Hoskins, Elizabeth E ^a   Morreale, Richard J ^a   Werner, Stephen P ^a   Higginbotham, Jennifer M ^a   Laimins, Laimonis A ^b   Lambert, Paul F ^c   Brown, Darron R ^d   Gillison, Maura L ^e   Nuovo, Gerard J ^e   Witte, David P ^a   Kim, Mi Ok ^a   Davies, Stella M ^a   Mehta, Parinda A ^a   Kovacic, Melinda Butsch ^a   Wikenheiser Brokamp, Kathryn A ^a   Wells, Susanne I ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FANCONI ANEMIA GROUP A PROTEIN; FANCONI ANEMIA GROUP D2 PROTEIN; PROTEIN E7;

ARTICLE; BASAL CELL; CELL COMPARTMENTALIZATION; CELL DIFFERENTIATION; CELL EXPANSION; CELL PROLIFERATION; CONTROLLED STUDY; DNA REPLICATION; E7 GENE; FANCONI ANEMIA GROUP A GENE; FANCONI ANEMIA GROUP D2 GENE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE LOSS; GENE OVEREXPRESSION; GENE SILENCING; GENOMIC INSTABILITY; HUMAN; HUMAN CELL; KERATINOCYTE; LIFE CYCLE STAGE; NONHUMAN; PRIORITY JOURNAL; REGULATOR GENE; SIGNAL TRANSDUCTION; VIRUS ATTENUATION; VIRUS GENE; VIRUS REPLICATION; WART VIRUS;

BRAZIL; CARCINOMA, SQUAMOUS CELL; CELL LINE, TRANSFORMED; FANCONI ANEMIA; FANCONI ANEMIA COMPLEMENTATION GROUP A PROTEIN; FANCONI ANEMIA COMPLEMENTATION GROUP D2 PROTEIN; FEMALE; GENOME, VIRAL; HEAD AND NECK NEOPLASMS; HUMAN PAPILLOMAVIRUS 16; HUMANS; KERATINOCYTES; MALE; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS INFECTIONS; VIRUS REPLICATION;

HUMAN PAPILLOMAVIRUS; PAPILLOMAVIRIDAE;

EID: 84864381128     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00408-12     Document Type: Article

References (35)

1. Ang KK, et al. 2010. Human papillomavirus and survival of patients with oropharyngeal cancer. N. Engl. J. Med. 363:24-35.
2. Auerbach AD. 2009. Fanconi anemia and diagnosis. Mutat. Res. 668:4-10.
3. Bagby GC, Alter BP. 2006. Fanconi anemia. Semin. Hematol. 43:147-156.
4. Bedell MA, et al. 1991. Amplification of human papillomavirus genomes in vitro is dependent on epithelial differentiation. J. Virol. 65:2254-2260.
5. Bodily J, Laimins LA. 2011. Presistence of human papillomavirus infection: keys to malignant progression. Trends Microbiol. 19:33-39.
6. Bolick DR, et al. 2003. Laboratory implementation of human papillomavirus testing. Arch. Pathol. Lab Med. 127:984-990.
7. Chesson HW, Blandford JM, Gift TL, Tao G, Irwin KL. 2004. The estimated direct medical cost of sexually transmitted diseases among American youth, 2000. Persp. Sex. Reprod. Health 36:11-19.
8. de Araujo MR, et al. 2010. High prevalence of oral human papillomavirus infection in Fanconi's anemia patients. Oral Dis. 17:572-576.
9. Fagerlie SR, Bagby GC. 2006. Immune defects in Fanconi anemia. Crit. Rev. Immunol. 26:81-96.
10. Gillison M. 2010. HPV and its effect on head and neck cancer prognosis. Clin. Adv. Hematol. Oncol. 8:680-682.
11. Gravitt PE, et al. 2007. High load for most high risk human papillomavirus genotypes is associated with prevalent cervical cancer precursors but only HPV16 load predicts the development of incident disease. Int. J. Cancer 121:2787-2793.
12. Halbert CL, Demers GW, Galloway DA. 1991. The E7 gene of human papillomavirus type 16 is sufficient for immortalization of human epithelial cells. J. Virol. 65:473-478.
13. Hoskins EE, et al. 2008. Coordinate regulation of Fanconi anemia gene expression occurs through the Rb/E2F pathway. Oncogene 27:4798-4808.
14. Hoskins EE, et al. 2009. Fanconi anemia deficiency stimulates HPV-associated hyperplastic growth in organotypic epithelial raft culture.Oncogene28:674-685.
15. Jones DL, Thompson DA, Munger K. 1997. Destabilization of the RB tumor suppressor protein and stabilization of p53 contribute to HPV type 16 E7-induced apoptosis. Virology 239:97-107.
16. Kennedy RD, D'Andrea AD. 2005. The Fanconi anemia/BRCA pathway: new faces in the crowd. Genes Dev. 19:2925-2940.
17. Kim Y, et al. 2011. Mutations of the SLX4 gene in Fanconi anemia. Nat. Genet. 43:142-146.
18. Kovacic MB, et al. 2006. Relationships of human papillomavirus type, qualitative viral load, and age with cytologic abnormality. Cancer Res. 66:10112-10119.
19. Kutler DI, et al. 2003. Human papillomavirus DNA and p53 polymorphisms in squamous cell carcinomas from Fanconi anemia patients. J. Natl. Cancer Inst. 95:1718-1721.
20. Leemans CR, Braakhuis BJM, Brakenhoff RH. 2011. The molecular biology of head and neck cancer. Nat. Rev. 11:9-22.
21. Lowy DR, Munger K. 2010. Prognostic implications of HPV in oropharyngeal cancer. N. Engl. J. Med. 363:82-84.
22. Mathew CG. 2006. Fanconi anaemia genes and susceptibility to cancer. Oncogene 25:5875-5884.
23. Melar-New M, Laimins LA. 2010. Human papillomaviruses modulate expression of microRNA 203 upon epithelial differentiation to control levels of p63 proteins. J. Virol. 84:5212-5221.
24. Mighty KK, Laimins LA. 2011. p63 is necessary for the activation of human papillomavirus late viral functions upon epithelial differentiation. J. Virol. 85:8863-8869.
25. Nakahara T, Peh WL, Doorbar J, Lee D, Lambert PF. 2005. Human papillomavirus type 16 E1circumflexE4 contributes to multiple facets of the papillomavirus life cycle. J. Virol. 79:13150-13165.
26. Park JW, et al. 2010. Deficiencies in the Fanconi anemia DNA damage response pathway increase sensitivity to HPV-associated head and neck cancer. Cancer Res. 70:9959-9968.
27. Spardy N, et al. 2007. The human papillomavirus type 16 E7 oncoprotein activates the Fanconi anemia (FA) pathway and causes accelerated chromosomal instability in FA cells. J. Virol. 81:13265-13270.
28. Spardy N, Duensing A, Hoskins EE, Wells SI, Duensing S. 2008. HPV-16 E7 reveals a link betweenDNAreplication stress, Fanconi anemia D2 protein, and alternative lengthening of telomere-associated promyelocytic leukemia bodies. Cancer Res. 68:9954-9963.
29. Stoepker C, et al. 2011. SLX4, a coordinator of structure-specific endonucleases, is mutated in a new Fanconi anemia subtype. Nat. Genet. 43:138-141.
30. Truong AB, Kretz M, Ridky TW, Kimmel R, Khavari PA. 2006. p63 regulates proliferation and differentiation of developmentally mature keratinocytes. Genes Dev. 20:3185-3197.
31. van Zeeburg HJ, et al. 2008. Clinical and molecular characteristics of squamous cell carcinomas from Fanconi anemia patients. J. Natl. Cancer Inst. 100:1649-1653.
32. Wang SS, et al. 2009. Common variants in immune and DNA repair genes and risk for human papillomavirus persistence and progression to cervical cancer. J. Infect. Dis. 199:20-30.
33. Wilson R, Laimins LA. 2005. Differentiation of HPV-containing cells using organotypic "raft" culture or methylcellulose. Methods Mol. Med. 119:157-169.
34. Wise-Draper TM, et al. 2006. Apoptosis inhibition by the human DEK oncoprotein involves interference with p53 functions. Mol. Cell. Biol. 26:7506-7519.
35. Wise-Draper TM, et al. 2009. DEK proto-oncogene expression interferes with the normal epithelial differentiation program. Am. J. Pathol. 174:71-81.